Laser Interstitial Thermal Therapy
Laser interstitial thermal therapy (LITT), also known as stereotactic laser amygdalohippocampotomy (SLAH) when applied to the mesial temporal structures, has emerged as the dominant minimally invasive ablative treatment for drug-resistant epilepsy in North America. The technique uses a stereotactically placed fiber optic probe to deliver laser energy, thermocoagulating the epileptogenic tissue under real-time MRI thermometry guidance. LITT offers several advantages over traditional open resective surgery: a smaller cranial access point, shorter hospitalization (typically 1–2 days), reduced pain, and potentially better preservation of neurocognitive function. However, these benefits come at the cost of somewhat lower seizure-freedom rates compared with standard anterior temporal lobectomy, with approximately 55–60% achieving Engel Class I outcomes for mesial temporal lobe epilepsy versus 60–70% with open surgery. LITT has expanded the therapeutic armamentarium for deep-seated lesions that are difficult to access via traditional surgical approaches, including hypothalamic hamartomas and periventricular nodular heterotopia.
Bottom Line
- Technique: MRI-guided stereotactic laser ablation using a fiber optic probe; real-time MRI thermometry provides precise control of ablation volume; performed under general anesthesia in an MRI suite
- Primary indication: Mesial temporal lobe epilepsy with hippocampal sclerosis (MTS) in patients who prefer a minimally invasive approach or when open surgery risks are higher
- MTLE outcomes: Engel I (seizure-free or auras only) in 55–60% at 1 year; lower than ATL (60–70%) but with potentially better cognitive preservation, especially naming and verbal memory
- Other indications: Hypothalamic hamartoma (gelastic seizures), focal cortical dysplasia, periventricular nodular heterotopia, cavernous malformations in deep or eloquent locations
- Advantages: Minimally invasive (3.2 mm burr hole), 1–2-day hospital stay, less pain, lower rates of naming and verbal memory dysfunction compared with open ATL
- Complications: Intracranial hemorrhage (~1.5%), visual field defects (8.8%), cranial neuropathies (3.1%, mostly transient CN III/IV palsies)
- SLATE trial: Prospective multicenter study of LITT for MTLE; demonstrated safety and efficacy with ≥43% Engel I outcomes as the equivalence threshold
Technique and Technology
System Components
Two FDA-cleared LITT systems are commercially available for intracranial use:
| Feature | Visualase (Medtronic) | NeuroBlate (Monteris Medical) |
|---|---|---|
| Laser type | 980 nm diode | 1064 nm Nd:YAG |
| Probe diameter | 1.65 mm (cooled diffusing tip) | 3.2 mm (side-firing or diffusing tip) |
| Ablation pattern | Cylindrical; diffuse tip creates ellipsoidal zone around probe | Side-firing tip allows directional ablation; useful for conforming to irregular targets |
| Cooling system | Internal CO2 gas cooling | Internal saline cooling |
| MRI thermometry | Real-time thermal damage estimate (TDE) maps displayed during ablation | Real-time thermal maps with damage threshold calculations |
| FDA clearance | 2009 | 2013 |
Procedural Steps
- Stereotactic planning: Preoperative MRI with volumetric sequences is used to plan the trajectory from the occipital or posterior temporal entry point to the target (e.g., hippocampal head and body for MTLE); trajectory is planned to maximize ablation coverage while avoiding vascular structures
- Frame or frameless registration: A stereotactic frame (Leksell, CRW) or frameless navigation system with robotic arm is used for trajectory guidance; accuracy is critical (<2 mm target error)
- Probe insertion: Under general anesthesia, a small twist-drill or burr hole (3.2 mm) is made at the entry point; the laser probe is advanced along the planned trajectory to the target under stereotactic guidance
- Transfer to MRI: The patient (with probe secured in place) is transferred to the MRI scanner; confirmatory imaging verifies probe position
- Laser ablation: Laser energy is delivered in sequential thermal doses; real-time MRI thermometry maps display tissue temperature and estimated ablation margins; the surgeon adjusts laser power, duration, and probe position to achieve the desired ablation volume while respecting thermal safety boundaries
- Post-ablation imaging: Immediate post-procedure MRI (T1 with gadolinium, FLAIR, DWI) documents ablation extent and checks for complications
- Recovery: The probe is removed, the burr hole is closed, and the patient typically recovers in the hospital for 1–2 days
Technical Keys to Successful LITT for MTLE
- Adequate hippocampal ablation: Ablation of the hippocampal head and body (and amygdala) is essential; incomplete ablation of the hippocampal head is the most common reason for surgical failure
- Ablation volume matters: Studies correlate ablation volume with seizure-freedom rates; the target volume for MTLE is approximately 60–70% of the hippocampus and most of the amygdala
- Thermal safety margins: The probe trajectory must avoid the brainstem, optic tract, and posterior cerebral artery; real-time thermometry allows the surgeon to halt ablation if temperatures approach critical structures
- Single vs. multiple trajectories: Some centers use a single occipitotemporal trajectory; others use dual trajectories (one for the amygdala, one for the hippocampal body/tail) to optimize coverage
- Learning curve: Outcomes improve with institutional experience; centers with higher LITT volumes report better seizure-freedom rates
Indications and Outcomes by Pathology
Mesial Temporal Lobe Epilepsy
LITT/SLAH for MTLE is the most common and best-studied application. The target population includes patients with drug-resistant MTLE who would otherwise undergo anterior temporal lobectomy but prefer a minimally invasive approach, or those in whom open surgery carries elevated risk.
| Study | Patients | Engel I Rate | Follow-up | Key Findings |
|---|---|---|---|---|
| SLATE trial (prospective multicenter) | 114 treated (107 completed) | ~58% | 12 months | Equivalence threshold met (≥43% Engel I); enrolled 167 across 21 US sites; demonstrated safety and efficacy of LITT for MTLE with MTS |
| Meta-analysis (Kohlhase 2021) | Pooled from multiple series | ~52–58% | 12–24 months | LITT achieves lower seizure-freedom rate than ATL (~65%) but with lower surgical complication rates |
| Single-center series with SEEG-confirmed onset | Variable | Up to 62–83% in select series | 12–24 months | Better outcomes when hippocampal seizure onset is confirmed by SEEG before LITT; ~97% achieved >50% seizure reduction in one SEEG-guided series |
| MTS vs. non-MTS on MRI | Varies | ~60% (MTS) vs. ~50% (non-MTS) | 12 months | Hippocampal sclerosis on MRI is a favorable predictor; non-MTS patients may benefit from SEEG confirmation of mesial onset before LITT |
Comparison: LITT/SLAH vs. Open ATL for MTLE
| Feature | LITT/SLAH | Open ATL |
|---|---|---|
| Engel I at 1 year | 55–60% | 60–70% |
| Hospital stay | 1–2 days | 3–5 days |
| Cranial access | 3.2 mm burr hole | Craniotomy (6–8 cm) |
| Naming decline (dominant side) | Lower risk; better object recognition and naming outcomes | 34% reduction in naming |
| Verbal memory decline (dominant side) | Superior verbal memory outcomes; sparing of lateral temporal neocortex | Up to 44% with left ATL |
| Visual field defect | 8.8% (usually superior quadrantanopia from probe trajectory near optic radiation) | 18% (disruption of Meyer loop during temporal resection) |
| Hemorrhage risk | ~1.5% | ~2–3% |
| Return to work/activities | 1–2 weeks | 4–6 weeks |
| Salvage option after failure | Open ATL remains feasible (prior LITT does not preclude subsequent open surgery) | Limited revision options |
When to Choose LITT vs. Open ATL for MTLE
- Favor LITT: Patient strongly prefers minimally invasive approach; dominant hemisphere surgery where cognitive preservation is paramount; patient needs rapid return to work or school; older or medically fragile patients who may not tolerate craniotomy well; bilateral MTLE where staged approaches are planned (LITT on one side, RNS contralaterally)
- Favor open ATL: Maximizing seizure-freedom probability is the highest priority; concurrent neocortical resection is needed (dual pathology); non-MTS MTLE without SEEG confirmation of mesial onset; center has limited LITT experience
- Salvage strategy: If LITT fails to achieve seizure freedom, open ATL can be performed subsequently with similar outcomes to primary ATL—LITT does not "burn bridges"
Hypothalamic Hamartoma
Hypothalamic hamartomas (HH) are rare congenital lesions that cause gelastic (laughing) seizures, which are often drug-resistant and may progress to other seizure types. These deep-seated, midline lesions are difficult to access via open surgical approaches, and traditional surgical series reported significant complication rates including hypothalamic dysfunction, endocrinopathy, and memory deficits. LITT has transformed the treatment of HH:
- Seizure-freedom rates: 60–80% in experienced centers; comparable to or better than open/endoscopic approaches with lower complication rates
- Advantages: The stereotactic approach reaches the deep hypothalamic location with minimal tissue disruption; multiple trajectories can be used for larger hamartomas
- Complications: Lower rates of hypothalamic dysfunction, endocrinopathy, and memory deficits compared with open procedures at experienced centers
- Some centers consider LITT first-line treatment for seizures due to hypothalamic hamartoma
Focal Cortical Dysplasia
LITT can be used for focal cortical dysplasia (FCD), particularly when the lesion is small, well-circumscribed, and located in a deep or surgically challenging location. Key considerations:
- FCD type II (with balloon cells) is the most favorable substrate; the lesion is often well-demarcated and completely ablatable
- Bottom-of-sulcus dysplasia (a common FCD type II morphology) is particularly amenable to LITT because the small, deep lesion can be ablated with a single trajectory
- Outcomes: Variable (40–70% Engel I); complete ablation of the lesion and surrounding dysplastic cortex is essential; ablation margins should be verified on post-procedure MRI
- Limitation: Large or poorly defined FCD may be better treated with open resection, which allows more complete removal guided by ECoG
Periventricular Nodular Heterotopia
Periventricular nodular heterotopia (PVNH) consists of collections of gray matter lining the lateral ventricles that can serve as independent seizure generators or participate in epileptogenic networks with overlying cortex. Traditional surgical approaches to PVNH require deep cortical dissection with risk of vascular injury and neurologic deficit. LITT provides a minimally invasive route to these deep targets:
- Outcomes: Limited published data; small series report 50–70% seizure reduction; seizure freedom rates are lower than for MTLE
- Consideration: PVNH-related epilepsy often involves complex networks; SEEG may be needed to determine whether the heterotopic nodule is the primary seizure generator or a secondary participant
- Combination approach: LITT of the nodule combined with overlying cortical resection may improve outcomes in selected cases
Complications and Limitations
Complications
| Complication | Incidence | Notes |
|---|---|---|
| Intracranial hemorrhage | ~1.5% | Related to probe insertion; most are small and asymptomatic; rarely requires surgical evacuation |
| Visual field defect | 8.8% | Superior quadrantanopia from thermal injury to optic radiation along the probe trajectory; comparable to but possibly lower than ATL rate (18%) |
| Cranial neuropathy | 3.1% | Mostly transient CN III and IV palsies from thermal effects near the tentorial edge; typically resolve within weeks to months |
| Infection | <1% | Very low risk given the small access point and short operative time |
| Hyponatremia (post-MTLE ablation) | Variable | SIADH-like syndrome; monitor sodium in the perioperative period; usually self-limited |
| Thermal injury beyond target | Rare | Risk of injury to adjacent structures (brainstem, thalamus, internal capsule) if thermal monitoring is inadequate; real-time MRI thermometry is the primary safety mechanism |
Limitations of LITT
- Lower seizure-freedom rate: ~55–60% Engel I for MTLE vs. ~60–70% for open ATL; patients must accept a somewhat lower probability of seizure freedom in exchange for the minimally invasive advantages
- Limited ablation volume: A single probe trajectory can ablate tissue within approximately 1–2 cm diameter; larger targets may require multiple trajectories or staged procedures, increasing complexity
- No intraoperative electrophysiology: Unlike open resection with ECoG, LITT does not provide real-time electrophysiologic feedback on completeness of resection
- MRI requirement: The procedure requires an intraoperative MRI suite, which is not universally available; this limits LITT to larger academic and specialized epilepsy centers
- Probe trajectory constraints: The entry-to-target trajectory must avoid major vessels (posterior cerebral artery, vein of Labbé) and critical structures; some anatomic configurations may not be favorable
- Not suitable for large lesions: Diffuse or large epileptogenic zones (extensive FCD, large tumors) are better treated with open resection
Cognitive Outcomes
One of the most compelling advantages of LITT over open ATL is the potential for superior neurocognitive preservation. The rationale is that LITT ablates only the mesial temporal structures while preserving the lateral temporal neocortex, which contains critical language and semantic memory networks. Key cognitive findings:
- Naming: Better object recognition and naming outcomes with LITT compared with ATL in language-dominant temporal lobe surgery; preservation of the basal temporal language area and inferior temporal gyrus may explain this advantage
- Verbal memory: Superior verbal memory outcomes after LITT compared with ATL for dominant-hemisphere MTLE; though some verbal memory decline can still occur, rates and severity appear lower
- Overall cognition: LITT is associated with lower rates of clinically significant cognitive decline across multiple domains compared with open ATL
- Caveats: Cognitive outcomes also depend on epilepsy etiology, seizure freedom (seizure recurrence itself impairs cognition), and individual anatomic variation; not all studies show significant differences between LITT and ATL for cognition
Other Minimally Invasive Ablative Techniques
Radiofrequency Thermocoagulation
Radiofrequency thermocoagulation (RFTC) delivers thermal energy through SEEG electrode contacts to ablate small volumes of tissue (typically 5–7 mm diameter per contact). RFTC can be performed at the time of SEEG monitoring, using the already-implanted electrodes to ablate the seizure-onset zone identified during the monitoring period. Key features:
- Advantages: No additional surgery required beyond the SEEG implantation; can be performed at the bedside; immediate feedback from post-coagulation ECoG
- Limitations: Ablation volume per contact is small; may be insufficient for large epileptogenic zones; best suited for small, discrete targets (e.g., small FCD, periventricular heterotopia)
- Outcomes: Seizure-freedom rates of 20–30% overall; better results for small, well-circumscribed targets; ~60% of patients who are not seizure-free still have worthwhile seizure reduction
- Role: Can serve as a minimally invasive first step; success may predict response to more extensive targeted resection or LITT
Stereotactic Radiosurgery
Gamma Knife radiosurgery delivers focused radiation to the epileptogenic target without an incision. It has been studied primarily for MTLE and hypothalamic hamartomas:
- MTLE outcomes: Seizure-freedom rates of 50–65% at 3 years, but delayed onset of effect (12–24 months before full benefit)
- Hypothalamic hamartoma: 40–60% seizure-freedom with lower complication rates than open surgery, but effects are delayed by months
- Disadvantages: Delayed onset of seizure reduction; radiation-induced edema may cause transient worsening at 10–15 months; cannot monitor ablation in real time; radiation dose to surrounding brain tissue
- Current role: Less commonly used than LITT in North America; may be an option when LITT or open surgery is not feasible
Postoperative Management After LITT
Immediate Postoperative Care
- Neurological monitoring: Frequent neurological examinations for the first 24 hours; visual field testing if temporal or occipital trajectory was used
- Steroids: Dexamethasone is commonly administered for 3–7 days to reduce periablational edema
- Sodium monitoring: Check sodium levels on postoperative day 1 and 3; SIADH-like hyponatremia may develop, particularly after mesial temporal ablation
- Seizure medications: Continue preoperative antiseizure medications; some centers add a short course of additional prophylaxis
- Discharge: Most patients are discharged within 24–48 hours; some centers discharge the same day for uncomplicated cases
Follow-Up Schedule
| Timepoint | Assessment | Key Considerations |
|---|---|---|
| 2–4 weeks | Wound check, seizure diary review, neurologic examination | Early postoperative seizures may occur and do not necessarily predict failure; monitor for steroid side effects |
| 3 months | MRI (FLAIR + T1 post-contrast), EEG, clinical assessment | Confirm ablation volume on MRI; periablational edema should be resolving; assess for new visual field defects |
| 6 months | Clinical assessment, seizure frequency review | Most patients have reached stable seizure outcome by this time; consider neuropsychological testing |
| 12 months | MRI, neuropsychological testing, Engel classification | Standard endpoint for outcome assessment; if not seizure-free, discuss options (medication optimization, repeat LITT, open ATL, neuromodulation) |
| Annually thereafter | Clinical assessment, seizure monitoring, driving/employment status | Late seizure recurrence can occur; medication taper may be considered after 1–2 years of seizure freedom |
Management of LITT Failure
If seizure freedom is not achieved after LITT, several options should be considered:
- Re-evaluate ablation completeness: Postoperative MRI may reveal incomplete ablation of the hippocampal head or inadequate amygdala ablation; repeat LITT can be considered for residual target tissue
- Open ATL as salvage: Standard anterior temporal lobectomy can be performed after LITT failure with outcomes comparable to primary ATL; the prior ablation does not compromise the surgical field
- Neuromodulation: If the patient is not a candidate for further resection, RNS or VNS may be considered as palliative options
- Medication optimization: Even if seizure freedom is not achieved, the seizure burden may be reduced sufficiently to try different medication combinations
Emerging Applications
LITT for Corpus Callosotomy
LITT has been applied to callosotomy as a minimally invasive alternative to open corpus callosotomy for patients with drop attacks. Early case series suggest comparable efficacy for drop seizure reduction with shorter hospitalization and potentially fewer complications related to the open surgical approach. However, complete callosal ablation with LITT may require multiple trajectories, and long-term comparative data are still lacking.
LITT for Insular Epilepsy
The insula is a challenging surgical target due to its deep location surrounded by the MCA branches. LITT can access insular lesions (FCD, cavernomas) through a trans-opercular trajectory, avoiding the need for extensive sylvian fissure dissection. Preliminary data suggest feasibility and safety, though seizure-freedom rates for insular epilepsy remain lower than for temporal lobe targets regardless of surgical approach.
LITT as a Staged Strategy
An emerging paradigm uses LITT as an initial minimally invasive step in a staged surgical strategy:
- LITT first, open ATL if needed: Patients undergo LITT as the initial procedure; if seizure freedom is not achieved after 6–12 months, open ATL can be performed as a salvage procedure without compromised outcomes
- LITT + RNS: In bilateral MTLE, LITT can ablate the dominant seizure focus while RNS monitors and treats the contralateral focus
- SEEG followed by LITT: SEEG data confirm the seizure-onset zone, and LITT is performed during the same hospitalization or as a planned second procedure
Patient Counseling Points for LITT
- "LITT offers a minimally invasive approach with less pain, shorter hospital stay, and faster recovery compared with open surgery"
- "The trade-off is a slightly lower probability of seizure freedom—about 55–60% compared with 60–70% with open surgery"
- "LITT may better preserve naming and verbal memory, which is especially important for dominant-hemisphere surgery"
- "If LITT does not achieve seizure freedom, open surgery remains an option—we are not limiting future treatment possibilities"
- "The hospital stay is typically 1–2 days, and most patients return to normal activities within 1–2 weeks"
- "Complications are uncommon but can include visual field changes, headache, and rarely hemorrhage"
References
- Friedman D, Engel J. Surgical treatments, devices, and nonmedical management of epilepsy. Continuum (Minneap Minn) 2025;31(1):165–186.
- Gross RE, Willie JT, Drane DL. The role of stereotactic laser amygdalohippocampotomy in mesial temporal lobe epilepsy. Neurosurg Clin N Am 2016;27(1):37–50.
- Kohlhase K, Zöllner JP, Tandon N, Strzelczyk A, Rosenow F. Comparison of minimally invasive and traditional surgical approaches for refractory mesial temporal lobe epilepsy: a systematic review and meta-analysis of outcomes. Epilepsia 2021;62(4):831–845.
- Willie JT, Laxpati NG, Drane DL, et al. Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery 2014;74(6):569–584.
- Drane DL, Loring DW, Voets NL, et al. Better object recognition and naming outcome with MRI-guided stereotactic laser amygdalohippocampotomy for temporal lobe epilepsy. Epilepsia 2015;56(1):101–113.
- Drane DL, Willie JT, Pedersen NP, et al. Superior verbal memory outcome after stereotactic laser amygdalohippocampotomy. Front Neurol 2021;12:779495.
- Kang JY, Wu C, Tracy J, et al. Laser interstitial thermal therapy for medically intractable mesial temporal lobe epilepsy. Epilepsia 2016;57(2):325–334.
- Jermakowicz WJ, Kanner AM, Sur S, et al. Laser thermal ablation for mesiotemporal epilepsy: analysis of the procedural learning curve. Neurosurgery 2017;80(2):217–224.
- Du VX, Gandhi SV, Rekate HL, Mehta AD. Laser interstitial thermal therapy: a first line treatment for seizures due to hypothalamic hamartoma? Epilepsia 2017;58(Suppl 2):77–84.
- Curry DJ, Raskin J, Ali I, Wilfong AA. MR-guided laser ablation for the treatment of hypothalamic hamartomas. Epilepsy Res 2018;142:131–134.
- Barot N, Batra K, Zhang J, et al. Surgical outcomes between temporal, extratemporal epilepsies and hypothalamic hamartoma: systematic review and meta-analysis of MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy. J Neurol Neurosurg Psychiatry 2022;93(2):133–143.
- Whiting AC, Bingaman JR, Catapano JS, et al. Laser interstitial thermal therapy for epileptogenic periventricular nodular heterotopia. World Neurosurg 2020;138:e892–e897.
- Treiber JM, Bayley JC, Curry D. Minimally invasive destructive, ablative, and disconnective epilepsy surgery. J Pediatr Epilepsy 2023;12(1):29–40.
- Josephson CB, Dykeman J, Fiest KM, et al. Systematic review and meta-analysis of standard vs selective temporal lobe epilepsy surgery. Neurology 2013;80(18):1669–1676.
- Awad AJ, Kaiser KN. Laser ablation for corpus callosotomy: systematic review and pooled analysis. Seizure 2022;96:137–141.